ARTICLE | Product Development
Clinical Report: U.K. details plans to improve clinical trial infrastructure
Plus: Neurocrine’s schizophrenia therapy, Medicxi-backed Vaderis’ treatment for rare vascular disorder both look to advance; plus a miss for Leo’s Timber
August 28, 2024 11:38 PM UTC
As the U.K. looks to bolster its clinical trial capabilities, Neurocrine and Vaderis are eyeing pivotal studies after reporting Phase II results, while Leo’s Timber reported a setback in the clinic.
The U.K. government has launched a public-private investment program that aims in large part to improve the country’s clinical trial infrastructure, as well as invest in next-generation manufacturing and modernize the health technology assessment (HTA) process. The initiative is part of the country’s latest five-year voluntary scheme for pricing of branded medicines pricing, access and growth (VPAG) that covers the sales of branded medicines in the U.K. through December 2028, as announced last November...